» Articles » PMID: 29223787

A Novel Peptide-based Vaccine Candidate with Protective Efficacy Against Influenza A in a Mouse Model

Overview
Journal Virology
Specialty Microbiology
Date 2017 Dec 11
PMID 29223787
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Current influenza vaccines mainly induce antibody responses to the variable hemagglutinin proteins of the virus strains included in the vaccine. Instead, a broadly protective influenza vaccine should aim at inducing antibody- and/or cell-mediated immunity against conserved viral proteins. Vacc-FLU is a peptide based vaccine combining conserved B and T cell epitopes. Peptide selection was done using a proprietary peptide design platform technology focusing on responses to human leukocyte antigen (HLA)-restricted epitopes. Immunization of wild-type mice and mice transgenic for HLA-A2.1 with the peptide mix successfully induced both humoral and cell mediated immune responses. Partial protection from severe weight loss upon challenge was observed in both mouse strains but was stronger and observed at lower vaccine doses in transgenic mice. Our results show that the Vacc-FLU peptide mix is capable of inducing IFNγ-producing T cells and antibody-producing B cells which can protect from severe disease symptoms upon infection.

Citing Articles

Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.

Zhao Y, Guo S, Liu J, Wang Y, Wang B, Peng C Front Immunol. 2025; 16:1519866.

PMID: 39958330 PMC: 11827429. DOI: 10.3389/fimmu.2025.1519866.


Microfluidic digital focus assays for the quantification of infectious influenza virus.

Srimathi S, Ignacio M, Rife M, Tai S, Milton D, Scull M Lab Chip. 2025; .

PMID: 39907221 PMC: 11796355. DOI: 10.1039/d4lc00940a.


Evaluation of the Safety and Immunogenicity of a Multiple Epitope Polypeptide from Canine Distemper Virus (CDV) in Mice.

Rendon-Marin S, Rincon-Tabares D, Tabares-Guevara J, Arbelaez N, Forero-Duarte J, Diaz F Vaccines (Basel). 2024; 12(10).

PMID: 39460307 PMC: 11511104. DOI: 10.3390/vaccines12101140.


Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.

Lim C, Komarasamy T, Binti Adnan N, Radhakrishnan A, Balasubramaniam V Influenza Other Respir Viruses. 2024; 18(3):e13276.

PMID: 38513364 PMC: 10957243. DOI: 10.1111/irv.13276.


Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2.

Li R, Chang Z, Liu H, Wang Y, Li M, Chen Y J Nanobiotechnology. 2024; 22(1):44.

PMID: 38291444 PMC: 10825999. DOI: 10.1186/s12951-024-02293-y.